281 related articles for article (PubMed ID: 26256079)
1. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
Wang L; Yao M; Pan LH; Qian Q; Yao DF
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
[TBL] [Abstract][Full Text] [Related]
2. Down-regulating glypican-3 expression: molecular-targeted therapy for hepatocellular carcinoma.
Dong Z; Yao M; Wang L; Yang J; Yao D
Mini Rev Med Chem; 2014; 14(14):1183-93. PubMed ID: 25553423
[TBL] [Abstract][Full Text] [Related]
3. Advances in the study of oncofetal antigen glypican-3 expression in HBV-related hepatocellular carcinoma.
Yao M; Wang L; Fang M; Zheng W; Dong Z; Yao D
Biosci Trends; 2016 Nov; 10(5):337-343. PubMed ID: 27795482
[TBL] [Abstract][Full Text] [Related]
4. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
[TBL] [Abstract][Full Text] [Related]
5. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma.
Yao M; Yao DF; Bian YZ; Wu W; Yan XD; Yu DD; Qiu LW; Yang JL; Zhang HJ; Sai WL; Chen J
Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):171-9. PubMed ID: 23558072
[TBL] [Abstract][Full Text] [Related]
6. Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma.
Wang L; Pan L; Yao M; Cai Y; Dong Z; Yao D
Oncotarget; 2016 Jul; 7(27):42150-42158. PubMed ID: 27286460
[TBL] [Abstract][Full Text] [Related]
7. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
Wang JY; Wang XK; Zhu GZ; Zhou X; Yao J; Ma XP; Wang B; Peng T
BMC Cancer; 2021 Apr; 21(1):462. PubMed ID: 33902495
[TBL] [Abstract][Full Text] [Related]
8. Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma (Review).
Montalbano M; Georgiadis J; Masterson AL; McGuire JT; Prajapati J; Shirafkan A; Rastellini C; Cicalese L
Oncol Rep; 2017 Mar; 37(3):1291-1300. PubMed ID: 28098909
[TBL] [Abstract][Full Text] [Related]
9. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.
Yao M; Wang L; Dong Z; Qian Q; Shi Y; Yu D; Wang S; Zheng W; Yao D
Tumour Biol; 2014 Jun; 35(6):5857-68. PubMed ID: 24633918
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis.
Shi XM; Teng F
Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588
[TBL] [Abstract][Full Text] [Related]
13. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line.
Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R
Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840
[TBL] [Abstract][Full Text] [Related]
15. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
Zhou F; Shang W; Yu X; Tian J
Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
17. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
18. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.
Cui X; Li Z; Gao PJ; Gao J; Zhu JY
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):157-63. PubMed ID: 25865688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
